MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2016 International Congress

    Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study

    M. Senek, D. Nyholm (Uppsala, Sweden)

    Objective: To compare the systemic levodopa exposure during administration of levodopa-entacapone-carbidopa (LECIG) intestinal gel with levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson's disease (PD) patients.…
  • 2016 International Congress

    Predicting therapeutic effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease

    J.B. Rowe, C. Rae, C. Nombela, T. Ham, P. Vazquez, I. Coyle-Gilchrist, C.R. Housden, B.J. Sahakian, T.W. Robbins, Z. Yes (Cambridge, United Kingdom)

    Objective: (1) To reassess the behavioral impact of novel noradrenergic (atomoxetine) and serotonergic (citalopram) therapies for impulsivity and (2) to develop predictive models to identify…
  • 2016 International Congress

    Diurnal variation of levodopa plasma concentration in patients with Parkinson’s disease

    M. Nagai, M. Kubo, H. Iwaki, R. Ando, H. Yabe, N. Nishikawa, M. Nomoto (Ehime, Japan)

    Objective: We analyzed diurnal variation of levodopa plasma concentration in large number of patients with Parkinson's disease (PD) to clarify the pattern of diurnal variation.…
  • 2016 International Congress

    Treatment of lipopolysaccharide-induced parkinsonism

    I. Niehaus (Rendsburg, Germany)

    Objective: This single case report of levodopa-responsive parkinsonism, caused by an accidental systemic contamination with 10 microgram lipopolysaccharides (LPS) from Salmonella minnesota, describes the treatment…
  • 2016 International Congress

    Suggested criteria for patient selection for therapy with carbidopa/levodopa enteral suspension (CLES)

    R.L. Rodriguez, T. Green, F. Rossi, A. Khaku, J. Slevin (Orlando, FL, USA)

    Objective: To provide suggested guidance on how to select appropriate candidates for therapy with carbidopa/levodopa enteral suspension (CLES) based on published literature. Background: The introduction…
  • 2016 International Congress

    Parkinson’s syndrome as possible manifestation of lamina quadrigemina tumor or inflammation

    N.M. Pavlyshyna, I.V. Khubetova (Odessa, Ukraine)

    Objective: Objective of this report is to discuss the case of Parkinson's syndrome (PS) in 22 y.o. patient on the background of the pathological process…
  • 2016 International Congress

    Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms

    B. Magennis, E.A. Donlon, E.M. Fallon, T. Lynch (Dublin, Ireland)

    Objective: To identify reasons for medication changes at outpatient movement disorder clinics and determine outcome of these changes at next clinic visit. Background: Parkinson's disease…
  • 2016 International Congress

    Patient-centered educational intervention using hand-held electronic devices

    N. Hellmers, A. Hanineva, J.C. Stribling, J. Carter, C. Henchliffe (New York, NY, USA)

    Objective: To examine feasibility, usability and initial efficacy of an e-learning intervention, using an interactive tablet-based slideshow with audio/video and quizzes. Background: Mobile tablet and…
  • 2016 International Congress

    The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

    J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

    Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…
  • 2016 International Congress

    Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension (nOH)

    C. Francois, K. McLeod, A. Duhig, A. Ogbonnaya, A. Quillen, J. Cannon, B. Padilla, C.A. Shibao, I. Biaggioni (Deerfield, IL, USA)

    Objective: To understand the characteristics of patients initiating droxidopa therapy for the treatment of neurogenic orthostatic hypotension (nOH). Background: nOH is defined as a fall…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley